Accueil   Diary - News   All news Adocia Initiates a Phase 1/2 Clinical Trial

Adocia Initiates a Phase 1/2 Clinical Trial

Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100

 

 

Adocia, announced today the initiation of a Phase 1b clinical trial to evaluate the post meal effects of HinsBet U100 in subjects with type 1 diabetes. HinsBet is a rapid-acting formulation of recombinant human insulin using Adocia’s proprietary technology BioChaperone, which is designed to accelerate insulin absorption. Another application of this technology, to accelerate insulin analogs such as insulin lispro, was licensed to Eli Lilly in December 2014. BioChaperone Lispro has shown an ultra-rapid profile, relative to Humalog® (insulin lispro, Lilly), in four Phase 1/2 clinical studies.

 

 

Read the press release